Group 1 - The core point of the article is that Qianjin Pharmaceutical has received approval for the registration certificate of hydrochloride rufinamide tablets from the National Medical Products Administration [1] - Qianjin Pharmaceutical's revenue composition for the first half of 2025 is as follows: 55.83% from drug production, 41.72% from drug wholesale and retail, 6.91% from other industries, 1.64% from traditional Chinese medicine materials and decoction pieces, and -6.1% from internal offsets [1] - As of the report date, Qianjin Pharmaceutical has a market capitalization of 5 billion yuan [1]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

Core Viewpoint - Qianjin Pharmaceutical (600479) announced that its subsidiary, Qianjin Xiangjiang Pharmaceutical, received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio aimed at treating schizophrenia [1] Group 1 - The approval of Lurasidone Hydrochloride Tablets marks a key milestone for the company in expanding its therapeutic offerings [1] - This product is specifically indicated for the treatment of schizophrenia, which addresses a critical area in mental health [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the psychiatric medication market [1] Group 1: Company Developments - The approval of Lurasidone Hydrochloride Tablets is aimed at treating schizophrenia, which broadens the therapeutic options available to patients [1] - The drug was originally developed by Sunovion Pharmaceuticals Inc. and was first launched in the United States in October 2010, with domestic import approval granted in January 2019 [1] - Other companies that have received registration for this drug in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] Group 2: Market Insights - According to Morin Data, the domestic market sales for Lurasidone Hydrochloride Tablets are projected to be approximately 52 million yuan in the first half of 2025, indicating a growing market potential for this medication [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Product Development - The Lurasidone Hydrochloride Tablets are indicated for the treatment of schizophrenia, originally developed by Sunovion Pharmaceuticals Inc. and launched in the U.S. in October 2010 [1] - The drug was approved for importation into China in January 2019, highlighting its potential in the domestic market [1] Group 2: Market Context - Other companies that have obtained the drug registration certificate in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] - According to data from MoSheng Pharmaceuticals, the estimated domestic market sales for Lurasidone Hydrochloride Tablets are approximately 52 million yuan in the first half of 2025, indicating a growing market opportunity [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, marking a significant milestone for the company in the psychiatric medication market [1] Group 1: Drug Approval and Market Context - The drug Lurasidone Hydrochloride Tablets is indicated for the treatment of schizophrenia and was originally developed by Sunovion Pharmaceuticals Inc., first launched in the U.S. in October 2010 and approved for import in China in January 2019 [1] - Other companies that have obtained registration for Lurasidone Hydrochloride Tablets in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] - According to data from MoSheng Pharmaceuticals, the domestic market sales for Lurasidone Hydrochloride Tablets are projected to be approximately 52 million yuan in the first half of 2025 [1] Group 2: R&D Investment - As of the date of the announcement, Qianjin Xiangjiang Pharmaceutical has invested a total of 6.3294 million yuan in the research and development of Lurasidone Hydrochloride Tablets [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, marking a significant milestone for the company in the psychiatric medication market [1] Company Summary - Qianjin Xiangjiang Pharmaceutical, a subsidiary of Qianjin Pharmaceutical, has been approved for Lurasidone Hydrochloride Tablets, which are used to treat schizophrenia [1] - The cumulative R&D investment by Qianjin Xiangjiang Pharmaceutical in Lurasidone Hydrochloride Tablets amounts to RMB 6.3294 million [1] Industry Summary - Lurasidone Hydrochloride Tablets were first developed by Sunovion Pharmaceuticals Inc. and launched in the U.S. in October 2010, with domestic approval for import in January 2019 [1] - Other companies that have obtained registration for Lurasidone Hydrochloride Tablets in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] - The domestic market sales for Lurasidone Hydrochloride Tablets are projected to be approximately RMB 52 million in the first half of 2025 [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, which is used for the treatment of schizophrenia, enhancing the company's product pipeline and supporting sustainable development [1] Company Summary - Qianjin Xiangjiang Pharmaceutical, a subsidiary of Qianjin Pharmaceutical, has invested a total of 6.3294 million yuan in the research and development of Lurasidone Hydrochloride Tablets [1] - The approval of Lurasidone Hydrochloride Tablets signifies that the product has passed the consistency evaluation, which is a positive development for the company's product offerings [1] Industry Summary - Other companies that have received the drug registration certificate for Lurasidone Hydrochloride Tablets include Jiangsu Hengrui Medicine Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., and Zhejiang Haizheng Pharmaceutical Co., Ltd. [1] - The production and sales of the drug are subject to significant uncertainties due to factors such as national policies and market environment changes [1]

Core Viewpoint - Qianjin Pharmaceutical's subsidiary, Qianjin Xiangjiang Pharmaceutical, has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, indicating a significant milestone in the company's product pipeline and potential for sustainable development [1] Group 1: Drug Registration and Development - The drug is indicated for the treatment of schizophrenia, with other companies such as Jiangsu Hengrui Medicine Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. also having obtained registration for the same drug [1] - Qianjin Xiangjiang Pharmaceutical has invested a total of 6.3294 million yuan in the research and development of Lurasidone Hydrochloride Tablets [1] Group 2: Market and Regulatory Environment - The approval of the drug registration certificate is considered equivalent to passing the consistency evaluation, which enhances the company's product offerings [1] - The production and sales of the drug are subject to significant uncertainties due to potential changes in national policies and market conditions [1]